Drawing for PANPHARMA

USPTO serial 79151519

PANPHARMA

Reviewed by CopyMark Law Group

Reg. 4774728Status 709
Filing date
Status date
Registration date
Jul 21, 2015
Examiner
SMITH, CYNTHIA RINALDI
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PANPHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of allergies, diseases related to the central nervous system, immune system diseases, autoimmune diseases, inflammatory diseases, rheumatoid arthritis, ankylosing spondilitis, obesity, diabetes, dyslipemia, brain diseases, locomotor disorders of the central nervous system, break down, multiple sclerosis, thrombosis and cancer, cardiovascular diseases, respiratory system diseases, digestive system diseases, haematological system and skeletal system diseases, psychiatric disorders, skin and subcutaneous tissue disorders, renal and urinary disorders, bronchial disorders, asthma, sinusitis, flu-like states, feverish aches, growth and mineralization disorders, veinolimphatic insufficiency and disorders, capillary fragility disorders, acute haemorroidal episodes, infectious conditions, travel sickness, healing of wounds and burns, sleep disorders, nausea and vomiting, constipation, diarrheas, intestinal disorders, nervousness, stress, hysteria, fears, anxiety and temporary tiredness, neurotonic conditions, gout, cold, rhinitis, cough, influenzas, rhinopharyngitis, sore throats, tracheitis, laryngitis and bacterial and non-bacterial anginas, hoarseness, kicks, lumps and contusions, eczema, cholesterol, degenerations, cutaneous and mucuous disorders, physical and psychic asthenia, menopause, menstruation-related disorders, allergic disorders, gynaecological diseases, rheumatic diseases, urological diseases, gastro-enterological diseases, ophtalmological diseases, dermatological diseases, genital diseases, endocrine diseases, intestinal diseases, blood-related diseases, diseases related to internal medicine, circulatory disorders, muscular disorders, nephropathy, pulmonary embolism, hypertension, atherothrombosis, arrythmia, hearing failure, epilepsy, schizophrenia, neurotic and psychosomatic disorders, hyperplasia, prostate, toxoplasmosis, malaria, malignant and benign tumors, hypercalcemia, hyperuremia, tuberculosis, whooping cough, diphtheria, poliomyelitis, rabies, allergic reactions, metabolic disorder, and control of allergic reactions or metabolic disorders; pharmaceutical preparations for smoking cessation, pharmaceutical sedatives, tranquilizers, depuratives for the body; vitamin, mineral supplements and vaccines for use on domestic animals and livestock for veterinary purposes; dietetic foods, namely, crackers, cakes, soup, meal replacement bars, fruit and vegetable granules adapted for medical use; pesticides, namely, preparations for destroying vermin within the province of the pharmaceutical sectorSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 13, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Oct 14, 2022INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Oct 14, 2022INPCINVALIDATION PROCESSED—
Oct 4, 2022INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 4, 2022C71TCANCELLED SECTION 71—
Dec 2, 2021RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 27, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 21, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 5, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 10, 2015XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Dec 10, 2015XXCRGENERIC MADRID TRANSACTION CREATED—
Oct 21, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 21, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 5, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 5, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 2, 2015GPNXNOTIFICATION PROCESSED BY IB—
Apr 15, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 15, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 15, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 28, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 23, 2015ALIEASSIGNED TO LIE—
Mar 4, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 3, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 3, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 3, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 3, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2014RFNTREFUSAL PROCESSED BY IB—
Sep 6, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 5, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 5, 2014RFRRREFUSAL PROCESSED BY MPU—
Sep 5, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 4, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2014DOCKASSIGNED TO EXAMINER—
Sep 2, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 28, 2014SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance